Patient perspectives on ipilimumab across the melanoma treatment trajectory
Carregando...
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2017
Editora
SPRINGER
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
SHUK, Elyse
SHOUSHTARI, Alexander N.
LUKE, Jason
POSTOW, Michael A.
CALLAHAN, Maggie
HARDING, James J.
ROTH, Katherine G.
FLAVIN, Marisa
GRANOBLES, Adrian
CHRISTIAN, Jana
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
SUPPORTIVE CARE IN CANCER, v.25, n.7, p.2155-2167, 2017
Resumo
Ipilimumab was the first FDA-approved agent for advanced melanoma to improve survival and represents a paradigm shift in melanoma and cancer treatment. Its unique toxicity profile and kinetics of treatment response raise novel patient education challenges. We assessed patient perceptions of ipilimumab therapy across the treatment trajectory. Four patient cohorts were assessed at different time points relative to treatment initiation: (1) prior to initiation of ipilimumab (n = 10), (2) at weeks 10-12 before restaging studies (n = 11), (3) at week 12 following restaging studies indicating progression of disease (n = 10), and (4) at week 12 following restaging studies indicating either a radiographic response or disease stability (n = 10). Patients participated in a semistructured qualitative interview to assess their experiences with ipilimumab. Quality of life was assessed via the Functional Assessment of Cancer Therapy-General and its Melanoma-specific module. Perceived quality of life was comparable across cohorts, and a majority of the sample understood side effects from ipilimumab and the potential for a delayed treatment response. Patients without progression of disease following restaging studies at week 12 held more positive views regarding ipilimumab compared to patients who had progressed. Patients generally regarded ipilimumab positively despite the risk of unique toxicities and potential for delayed therapeutic responses; however, those with progression expressed uncertainty regarding whether taking ipilimumab was worthwhile. Physician communication practices and patient education regarding realistic expectations for therapeutic benefit as well as unique toxicities associated with ipilimumab should be developed so that patients can better understand the possible outcomes from treatment.
Palavras-chave
Melanoma, Ipilimumab, Patient-reported quality of life, Qualitative research, FACT-M, FACT-G
Referências
- Balch CM, 2001, J CLIN ONCOL, V19, P3622
- BARTH A, 1995, J AM COLL SURGEONS, V181, pA193
- Bernard H. R., 2011, RES METHODS ANTHR QU
- Boyatzis RE, 2009, TRANSFORMING QUALITA
- Brinkmann Svend, 2015, INTERVIEWS LEARNING
- CELLA DF, 1993, J CLIN ONCOL, V11, P570
- Committee on Quality of Health Care in America I of M, 2001, CROSSING QUALITY CHA
- Cormier JN, 2011, SURG ONCOL CLIN N AM, V20, P201, DOI 10.1016/j.soc.2010.09.002
- Creswell J. W., 2013, QUALITATIVE INQUIRY
- Denzin Norman K., 2009, RES ACT THEORETICAL
- Friese S., 2014, QUALITATIVE DATA ANA
- Green J, 2014, QUALITATIVE METHODS
- Grob JJ, 2015, LANCET ONCOL, V16, P1389, DOI 10.1016/S1470-2045(15)00087-X
- Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903
- Hodi FS, 2010, NEW ENGL J MED, V363, P1290
- Maker AV, 2005, ANN SURG ONCOL, V12, P1005, DOI 10.1245/ASO.2005.03.536
- Miles M. B., 2014, QUALITATIVE DATA ANA
- Morse J. M., 2002, INT J QUAL METH, V1, P1
- Patton M., 2002, QUALITATIVE EVALUATI
- Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
- Saldana J., 2013, CODING MANUAL QUALIT
- Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736
- Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624